<DOC>
	<DOCNO>NCT00128661</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer form forming , grow , come back . Vaccines may help body build effective immune response human papillomavirus may effective prevent cervical intraepithelial neoplasia cervical cancer . It yet know whether human papillomavirus vaccine effective hepatitis A vaccine prevent cervical intraepithelial neoplasia cervical cancer . PURPOSE : This randomized phase III trial study human papillomavirus vaccine see well work compare hepatitis A vaccine prevent cervical intraepithelial neoplasia cervical cancer young healthy participant .</brief_summary>
	<brief_title>Vaccine To Prevent Cervical Intraepithelial Neoplasia Cervical Cancer Younger Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : Primary •Demonstrate efficacy candidate vaccine , human papillomavirus 16/18 ( HPV 16/18 ) L1 virus-like particle ( VLP ) /AS04 vaccine compare control prevent grade 2 3 cervical intraepithelial neoplasia , adenocarcinoma situ cervix , invasive cervical cancer ( CIN2+ ) associate HPV 16 HPV 18 cervical infection young healthy participant negative HPV DNA polymerase chain reaction ( PCR ) correspond HPV type month 0 6 . Secondary - Determine duration protection HPV 16 HPV 18 cervical infection participant treat HPV 16/18 L1 VLP/AS04 vaccine . - Determine safety vaccine participant , regardless initial HPV 16/18 DNA status . - Evaluate efficacy candidate vaccine , HPV 16/18 L1 VLP/AS04 vaccine compare control prevent CIN2+ associate oncogenic HPV type cervical infection participant negative HPV DNA PCR correspond HPV type month 0 6 . - Compare efficacy candidate vaccine control prevent CIN2+ associate HPV 16 HPV 18 cervical infection , detect within lesional component cervical tissue specimen PCR , participant negative HPV DNA PCR correspond HPV type month 0 6 enzyme-linked immunosorbent assay ( ELISA ) month 0 . - Compare efficacy candidate vaccine control prevent persistent HPV 16 HPV 18 cervical infection participant . - Determine immunogenicity HPV 16/18 L1 VLP/AS04 vaccine ELISA V5/J4 monoclonal antibody inhibition enzyme immunoassay first 600 participant randomize receive HPV 16/18 L1 VLP/AS04 vaccine . OUTLINE : This randomize , control , double-blind , parallel-group study . Participants randomize 1 2 treatment arm . - Arm I : Participants receive human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine intramuscularly ( IM ) month 0 , 1 , 6 . - Arm II : Participants receive hepatitis A vaccine ( Havrix® ) IM month 0 , 1 , 6 . After completion study treatment , participant follow 6 month least annually 3 year . PROJECTED ACCRUAL : Approximately 7,500 participant accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : •Healthy participant Deemed good general health history physical examination •Resident Guanacaste Province Costa Rica surround area Must remain resident ≥ 6 month first study vaccination PATIENT CHARACTERISTICS : Age 18 25 Performance status •Not specify Life expectancy •Not specify Hematopoietic •Not specify Hepatic No history chronic hepatitis require treatment No acute chronic clinically significant hepatic function abnormality physical examination laboratory find No known history hepatitis A infection Renal No history kidney disease require treatment No acute chronic clinically significant kidney function abnormality physical examination laboratory finding Cardiovascular No acute chronic clinically significant cardiovascular function abnormality physical examination laboratory finding Pulmonary No acute chronic clinically significant pulmonary function abnormality physical examination laboratory finding Immunology No history allergic disease No history autoimmune disorder require treatment No history allergic reaction ( e.g. , difficulty breathe ) vaccine No suspect allergy reaction likely exacerbate component study vaccine ( e.g. , 2phenoxyethanol neomycin ) No hypersensitivity latex No diagnosis suspicion immunodeficient condition medical history physical examination Other Not pregnant nursing ◦No delivery within past 3 month Negative pregnancy test Fertile patient must use effective contraception 30 day , , 60 day completion study treatment Able speak understand Spanish Mentally competent Able undergo pelvic exam ( i.e. , heavy bleeding [ menstruation otherwise ] heavy vaginal discharge ) No history cancer require treatment No history diabetes require treatment No history chronic condition require treatment No acute chronic clinically significant neurologic function abnormality physical examination laboratory find No acute disease No fever ≥ 37.5º C PRIOR CONCURRENT THERAPY : Biologic therapy More 6 month since prior chronic administration ( i.e. , &gt; 14 day ) immunemodulating drug More 90 day since prior immunoglobulin More 30 day since prior concurrent investigational nonregistered vaccine More 30 day since prior register vaccine More 8 day since prior routine meningococcal , hepatitis B , influenza , diphtheria/tetanus vaccine No prior vaccination hepatitis A No prior vaccination human papillomavirus No prior monophosphoryl lipid A AS04 adjuvant Chemotherapy •Not specify Endocrine therapy More 6 month since prior chronic administration ( i.e. , &gt; 14 day ) corticosteroid ( e.g. , ≥ 0.5 mg/kg/day prednisone equivalent ) Concurrent inhale topical steroid allow Radiotherapy •Not specify Surgery •No prior hysterectomy Other More 6 month since prior chronic administration ( i.e. , &gt; 14 day ) immunosuppressant More 30 day since prior concurrent investigational nonregistered drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cervical intraepithelial neoplasia grade 2</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
</DOC>